You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 9,399,028

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,399,028

Title:	Treatment of drug resistant cancer
Abstract:	The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Inventor(s):	Tavazoie; Sohail (New York, NY), Pencheva; Nora (New York, NY)
Assignee:	The Rockefeller University (New York, NY)
Application Number:	14/486,466
Patent Claims:	1. A method of treating drug resistant cancer in a subject in need thereof, comprising administering to the subject an effective amount of an LXR.beta. agonist, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor or PD-L1 inhibitor, wherein said inhibitor is nivolumab or atezolizumab (MPDL3280A), wherein said drug resistant cancer is breast cancer, non-small cell lung cancer, or ovarian cancer, and wherein said LXR.beta. agonist is: ##STR00020## 2. The method of claim 1, wherein said drug resistant cancer is metastatic. 3. The method of claim 1, comprising administration of an additional anticancer therapy. 4. The method of claim 3, wherein said additional anticancer therapy is an antiproliferative. 5. The method of claim 4, wherein said antiproliferative is a VEGF inhibitor, a VEGFR2 inhibitor, and/or a CTLA4 inhibitor. 6. The method of claim 3, wherein said antiproliferative is ipilmumab or vemurafenib. 7. The method of claim 1, wherein said LXR.beta. agonist is administered in an amount sufficient to slow the spread of said drug resistant cancer. 8. The method of claim 2, wherein said LXR.beta. agonist is administered in an amount sufficient to increase the expression level or activity level of ApoE to a level sufficient to slow the spread of metastasis of said drug resistant cancer. 9. The method of claim 1, wherein said drug resistant cancer is ovarian cancer. 10. The method of claim 9, wherein said ovarian cancer is resistant to platinum agents. 11. The method of claim 1, wherein said drug resistant cancer is breast cancer. 12. The method of claim 11, wherein said breast cancer is triple negative breast cancer. 13. The method of claim 1, wherein said drug resistant cancer is non-small cell lung cancer. 14. The method of claim 1, wherein the subject is administered an effective amount of an LXR.beta. agonist, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, wherein the PD-1 inhibitor is nivolumab. 15. The method of claim 1, wherein the subject is administered an effective amount of an LXR.beta. agonist, or a pharmaceutically acceptable salt thereof, and a PD-L1 inhibitor, wherein the PD-L1 inhibitor is atezolizumab (MPDL3280A).

Details for Patent 9,399,028

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014	⤷ Try a Trial	2032-08-13
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017	⤷ Try a Trial	2032-08-13
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021	⤷ Try a Trial	2032-08-13
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034	05/18/2016	⤷ Try a Trial	2032-08-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.